{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:32:47Z","timestamp":1787668367646,"version":"build-2736575974"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol. Res. Pract."],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Kappa free light chains (KFLC), a byproduct of immunoglobulin (Ig) synthesis by B-lineage cells, can serve as an indicator for inflammatory activity. In multiple sclerosis (MS), especially the intrathecal KFLC production has gained increasing importance as a biomarker for central nervous system (CNS) inflammation and was included into the proposed 2024 revision of the McDonald criteria. In contrast, studies investigating the significance of KFLC in serum and the effects of disease-modifying therapies (DMT) on KFLC serum concentration in MS are rare. The aim of the present work was to investigate the impact of B cell depletion with ocrelizumab on KFLC concentrations in serum of MS patients and the ability of serum KFLC to monitor disease activity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>50 MS patients were included in the present study\u2013 38 with the diagnosis of relapsing MS (RMS) and 12 with diagnosis of primary-progressive MS (PPMS) -, who were treated with ocrelizumab for two years. Serum concentrations of albumin, immunoglobulins and KFLC as well as lymphocyte subsets were determined at baseline and after two years.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Serum Ig and KFLC concentrations were found to be significantly lower after two years of ocrelizumab treatment (mean serum concentrations: KFLC: 9.5\u00a0mg\/l vs. 7.8\u00a0mg\/l, <jats:italic>p<\/jats:italic>\u2009=\u20090.0003; IgG: 9\u00a0g\/l vs. 8\u00a0g\/l, <jats:italic>p<\/jats:italic>\u2009=\u20090.0002; IgA: 2\u00a0g\/l vs. 1.8\u00a0g\/l, <jats:italic>p<\/jats:italic>\u2009=\u20090.0010; IgM: 1.8\u00a0g\/l vs. 0.7\u00a0g\/l, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). Serum KFLC concentration did not correlate with clinical and paraclinical parameters of disease activity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Treatment with ocrelizumab reduces serum KFLC concentration in MS patients. However, serum KFLC concentration is not able to predict disease activity in these MS patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s42466-025-00419-7","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T09:46:22Z","timestamp":1755855982000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Kappa free light chain concentration in serum is reduced after CD20-depletion with ocrelizumab"],"prefix":"10.1186","volume":"7","author":[{"given":"Franz Felix","family":"Konen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudrun Mechthild","family":"K\u00f6rner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin W.","family":"H\u00fcmmert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp Sebastian","family":"Gehring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Schwenkenbecher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin Fritz","family":"Jendretzky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Nay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"M\u00f6hn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Grote-Levi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt-Wolfram","family":"S\u00fchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Vo\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Refik","family":"Pul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Witte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Skripuletz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Gingele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,22]]},"reference":[{"issue":"11","key":"419_CR1","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/nrneph.2009.151","volume":"5","author":"CA Hutchison","year":"2009","unstructured":"Hutchison, C. A., Basnayake, K., & Cockwell, P. (2009). Serum free light chain assessment in monoclonal gammopathy and kidney disease. Nature Reviews Nephrology, 5(11), 621\u2013628. https:\/\/doi.org\/10.1038\/nrneph.2009.151","journal-title":"Nature Reviews Nephrology"},{"issue":"5","key":"419_CR2","doi-asserted-by":"publisher","first-page":"103765","DOI":"10.1016\/j.autrev.2025.103765","volume":"24","author":"FF Konen","year":"2025","unstructured":"Konen, F. F., Wurster, U., Schwenkenbecher, P., Gerritzen, A., Gro\u00df, C. C., Eichhorn, P., Harrer, A., Isenmann, S., Lewczuk, P., Lewerenz, J., Leypoldt, F., Otto, M., Regeniter, A., Roskos, M., Ruprecht, K., Spreer, A., Strik, H., Uhr, M., Wick, M., Wildemann, B., Wiltfang, J., Zimmermann, T., Hannich, M., Khalil, M., Tumani, H., S\u00fc\u00dfe, M., Skripuletz, T., & German Society for Cerebrospinal Fluid Diagnostics and Clinical Neurochemistry (DGLN e.V.). (2025). Oligoclonal bands and kappa free light chains: Competing parameters or complementary biomarkers? Autoimmunity Reviews, 24(5), 103765. https:\/\/doi.org\/10.1016\/j.autrev.2025.103765","journal-title":"Autoimmunity Reviews"},{"issue":"1","key":"419_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1136\/ard.2006.052159","volume":"66","author":"JE Gottenberg","year":"2007","unstructured":"Gottenberg, J. E., Aucouturier, F., Goetz, J., Sordet, C., Jahn, I., Busson, M., Cayuela, J. M., Sibilia, J., & Mariette, X. (2007). Serum Immunoglobulin free light chain assessment in rheumatoid arthritis and primary sjogren\u2019s syndrome. Annals of the Rheumatic Diseases, 66(1), 23\u201327. https:\/\/doi.org\/10.1136\/ard.2006.052159","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"10","key":"419_CR4","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.kjms.2013.01.013","volume":"29","author":"Y Ye","year":"2013","unstructured":"Ye, Y., Li, S. L., Xie, M., Jiang, P., Liu, K. G., & Li, Y. J. (2013). Judging disease activity in rheumatoid arthritis by serum free kappa and lambda light chain levels. The Kaohsiung Journal of Medical Sciences, 29(10), 547\u2013553. https:\/\/doi.org\/10.1016\/j.kjms.2013.01.013","journal-title":"The Kaohsiung Journal of Medical Sciences"},{"key":"419_CR5","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1100\/tsw.2011.65","volume":"11","author":"B Kaplan","year":"2011","unstructured":"Kaplan, B., Livneh, A., & Sela, B. A. (2011). Immunoglobulin free light chain dimers in human diseases. TheScientificWorldJournal, 11, 726\u2013735. https:\/\/doi.org\/10.1100\/tsw.2011.65","journal-title":"TheScientificWorldJournal"},{"issue":"12","key":"419_CR6","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1136\/ard.2009.126441","volume":"69","author":"TG Kormelink","year":"2010","unstructured":"Kormelink, T. G., Tekstra, J., Thurlings, R. M., Boumans, M. H., Vos, K., Tak, P. P., Bijlsma, J. W., Lafeber, F. P., Redegeld, F. A., & van Roon, J. A. (2010). Decrease in Immunoglobulin free light chains in patients with rheumatoid arthritis upon rituximab (anti-CD20) treatment correlates with decrease in disease activity. Annals of the Rheumatic Diseases, 69(12), 2137\u20132144. https:\/\/doi.org\/10.1136\/ard.2009.126441","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"10","key":"419_CR7","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1093\/rheumatology\/key180","volume":"57","author":"GM Verstappen","year":"2018","unstructured":"Verstappen, G. M., Moerman, R. V., van Nimwegen, J. F., van Ginkel, M. S., Bijzet, J., Mossel, E., Vissink, A., Hazenberg, B. P. C., Arends, S., Kroese, F. G. M., & Bootsma, H. (2018). Serum Immunoglobulin free light chains are sensitive biomarkers for monitoring disease activity and treatment response in primary sj\u00f6gren\u2019s syndrome. Rheumatology (Oxford England), 57(10), 1812\u20131821. https:\/\/doi.org\/10.1093\/rheumatology\/key180","journal-title":"Rheumatology (Oxford England)"},{"key":"419_CR8","unstructured":"Montalban, X. (2024). 2024 revisions of the McDonald criteria. ECTRIMS: 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 18\u201320 September 2024. https:\/\/ectrims.eu\/mcdonald-diagnostic-criteria. Accessed 5 November 2024."},{"issue":"7","key":"419_CR9","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41582-021-00498-5","volume":"17","author":"MT Cencioni","year":"2021","unstructured":"Cencioni, M. T., Mattoscio, M., Magliozzi, R., Bar-Or, A., & Muraro, P. A. (2021). B cells in multiple sclerosis - from targeted depletion to immune reconstitution therapies. Nature Reviews Neurology, 17(7), 399\u2013414. https:\/\/doi.org\/10.1038\/s41582-021-00498-5","journal-title":"Nature Reviews Neurology"},{"issue":"9","key":"419_CR10","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1111\/ene.13667","volume":"25","author":"M S\u00fc\u00dfe","year":"2018","unstructured":"S\u00fc\u00dfe, M., Hannich, M., Petersmann, A., Zylla, S., Pietzner, M., Nauck, M., & Dressel, A. (2018). Kappa free light chains in cerebrospinal fluid to identify patients with oligoclonal bands. European Journal of Neurology, 25(9), 1134\u20131139. https:\/\/doi.org\/10.1111\/ene.13667","journal-title":"European Journal of Neurology"},{"issue":"11\u201312","key":"419_CR11","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.cca.2011.03.007","volume":"412","author":"T Nakano","year":"2011","unstructured":"Nakano, T., Matsui, M., Inoue, I., Awata, T., Katayama, S., & Murakoshi, T. (2011). Free Immunoglobulin light chain: Its biology and implications in diseases. Clinica Chimica Acta; International Journal of Clinical Chemistry, 412(11\u201312), 843\u2013849. https:\/\/doi.org\/10.1016\/j.cca.2011.03.007","journal-title":"Clinica Chimica Acta; International Journal of Clinical Chemistry"},{"issue":"4","key":"419_CR12","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3390\/diagnostics9040194","volume":"9","author":"P Schwenkenbecher","year":"2019","unstructured":"Schwenkenbecher, P., Konen, F. F., Wurster, U., Witte, T., Gingele, S., S\u00fchs, K. W., Stangel, M., & Skripuletz, T. (2019). Reiber\u2019s diagram for kappa free light chains: The new standard for assessing intrathecal synthesis?? Diagnostics (Basel Switzerland), 9(4), 194. https:\/\/doi.org\/10.3390\/diagnostics9040194","journal-title":"Diagnostics (Basel Switzerland)"},{"key":"419_CR13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.msard.2016.01.001","volume":"6","author":"J Topping","year":"2016","unstructured":"Topping, J., Dobson, R., Lapin, S., Maslyanskiy, A., Kropshofer, H., Leppert, D., Giovannoni, G., & Evdoshenko, E. (2016). The effects of intrathecal rituximab on biomarkers in multiple sclerosis. Multiple Sclerosis and Related Disorders, 6, 49\u201353. https:\/\/doi.org\/10.1016\/j.msard.2016.01.001","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"3","key":"419_CR14","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1111\/jnc.15500","volume":"159","author":"I Rosenstein","year":"2021","unstructured":"Rosenstein, I., Rasch, S., Axelsson, M., Novakova, L., Blennow, K., Zetterberg, H., & Lycke, J. (2021). Kappa free light chain index as a diagnostic biomarker in multiple sclerosis: A real-world investigation. Journal of Neurochemistry, 159(3), 618\u2013628. https:\/\/doi.org\/10.1111\/jnc.15500","journal-title":"Journal of Neurochemistry"},{"key":"419_CR15","doi-asserted-by":"publisher","unstructured":"Rudick, R. A., Cookfair, D. L., Simonian, N. A., Ransohoff, R. M., Richert, J. R.,Jacobs, L. D., Herndon, R. M., Salazar, A. M., Fischer, J. S., Granger, C. V., Goodkin,D. E., Simon, J. H., Bartoszak, D. M., Bourdette, D. N., Braiman, J., Brownscheidle,C. M., Coats, M. E., Cohan, S. L., Dougherty, D. S., Kinkel, R. P., \u2026 Whitham, R.H. (1999). Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a)for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.Journal of neuroimmunology, 93(1\u20132), 8\u201314. https:\/\/doi.org\/10.1016\/s0165-5728(98)00174-x.","DOI":"10.1016\/s0165-5728(98)00174-x."},{"issue":"3","key":"419_CR16","doi-asserted-by":"publisher","first-page":"720","DOI":"10.3390\/diagnostics12030720","volume":"12","author":"M S\u00fc\u00dfe","year":"2022","unstructured":"S\u00fc\u00dfe, M., Konen, F. F., Schwenkenbecher, P., Budde, K., Nauck, M., Grothe, M., Hannich, M. J., & Skripuletz, T. (2022). Decreased intrathecal concentrations of free light chains kappa in multiple sclerosis patients taking very high effective Disease-Modifying treatment. Diagnostics (Basel Switzerland), 12(3), 720. https:\/\/doi.org\/10.3390\/diagnostics12030720","journal-title":"Diagnostics (Basel Switzerland)"},{"issue":"4","key":"419_CR17","doi-asserted-by":"publisher","first-page":"842","DOI":"10.3390\/cells9040842","volume":"9","author":"FF Konen","year":"2020","unstructured":"Konen, F. F., Wurster, U., Witte, T., Jendretzky, K. F., Gingele, S., Tumani, H., S\u00fchs, K. W., Stangel, M., Schwenkenbecher, P., & Skripuletz, T. (2020). The impact of Immunomodulatory treatment on kappa free light chains as biomarker in neuroinflammation. Cells, 9(4), 842. https:\/\/doi.org\/10.3390\/cells9040842","journal-title":"Cells"},{"issue":"1","key":"419_CR18","doi-asserted-by":"publisher","first-page":"20329","DOI":"10.1038\/s41598-020-77029-7","volume":"10","author":"D Vecchio","year":"2020","unstructured":"Vecchio, D., Bellomo, G., Serino, R., Virgilio, E., Lamonaca, M., Dianzani, U., Cantello, R., Comi, C., & Crespi, I. (2020). Intrathecal kappa free light chains as markers for multiple sclerosis. Scientific Reports, 10(1), 20329. https:\/\/doi.org\/10.1038\/s41598-020-77029-7","journal-title":"Scientific Reports"},{"key":"419_CR19","doi-asserted-by":"publisher","unstructured":"Hauser, S. L., Bar-Or, A., Comi, G., Giovannoni, G., Hartung, H. P., Hemmer, B.,Lublin, F., Montalban, X., Rammohan, K. W., Selmaj, K., Traboulsee, A., Wolinsky,J. S., Arnold, D. L., Klingelschmitt, G., Masterman, D., Fontoura, P., Belachew, S.,Chin, P., Mairon, N., Garren, H., \u2026 OPERA I and OPERA II Clinical Investigators (2017).Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. The New England journal of medicine, 376(3), 221\u2013234. https:\/\/doi.org\/10.1056\/NEJMoa1601277.","DOI":"10.1056\/NEJMoa1601277."},{"issue":"3","key":"419_CR20","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban, X., Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Comi, G., de Seze, J., Giovannoni, G., Hartung, H. P., Hemmer, B., Lublin, F., Rammohan, K. W., Selmaj, K., Traboulsee, A., Sauter, A., Masterman, D., Fontoura, P., Belachew, S., Garren, H., Mairon, N., & ORATORIO Clinical Investigators. (2017). Ocrelizumab versus placebo in primary progressive multiple sclerosis. The New England Journal of Medicine, 376(3), 209\u2013220. https:\/\/doi.org\/10.1056\/NEJMoa1606468","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"419_CR21","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/cells8010012","volume":"8","author":"S Gingele","year":"2018","unstructured":"Gingele, S., Jacobus, T. L., Konen, F. F., H\u00fcmmert, M. W., S\u00fchs, K. W., Schwenkenbecher, P., Ahlbrecht, J., M\u00f6hn, N., M\u00fcschen, L. H., B\u00f6nig, L., Alvermann, S., Schmidt, R. E., Stangel, M., Jacobs, R., & Skripuletz, T. (2018). Ocrelizumab depletes CD20\u207a T cells in multiple sclerosis patients. Cells, 8(1), 12. https:\/\/doi.org\/10.3390\/cells8010012","journal-title":"Cells"},{"issue":"6","key":"419_CR22","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1007\/s13311-023-01446-5","volume":"20","author":"SA Freeman","year":"2023","unstructured":"Freeman, S. A., Lemarchant, B., Alberto, T., Boucher, J., Outteryck, O., Labalette, M., Rogeau, S., Dubucquoi, S., & Z\u00e9phir, H. (2023). Assessing sustained B-Cell depletion and disease activity in a French multiple sclerosis cohort treated by Long-Term IV Anti-CD20 antibody therapy. Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics, 20(6), 1707\u20131722. https:\/\/doi.org\/10.1007\/s13311-023-01446-5","journal-title":"Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics"},{"key":"419_CR23","doi-asserted-by":"publisher","first-page":"103448","DOI":"10.1016\/j.msard.2021.103448","volume":"57","author":"D Baker","year":"2022","unstructured":"Baker, D., MacDougall, A., Kang, A. S., Schmierer, K., Giovannoni, G., & Dobson, R. (2022). CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis. Multiple Sclerosis and Related Disorders, 57, 103448. https:\/\/doi.org\/10.1016\/j.msard.2021.103448","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"1","key":"419_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s42466-025-00379-y","volume":"7","author":"A Mrochen","year":"2025","unstructured":"Mrochen, A., Meuth, S. G., & Pfeuffer, S. (2025). Should we stay or should we go? Recent insights on drug discontinuation in multiple sclerosis. Neurological Research and Practice, 7(1), 25. https:\/\/doi.org\/10.1186\/s42466-025-00379-y","journal-title":"Neurological Research and Practice"},{"key":"419_CR25","doi-asserted-by":"publisher","unstructured":"Bayas, A., Mansmann, U., \u00d6n, B. I., Hoffmann, V. S., Berthele, A., M\u00fchlau, M., Kowarik,M. C., Krumbholz, M., Senel, M., Steuerwald, V., Naumann, M., Hartberger, J., Kerschensteiner,M., Oswald, E., Ruschil, C., Ziemann, U., Tumani, H., Vardakas, I., Albashiti, F.,Kramer, F., \u2026 ProVal-MS study group (2024). Prospective study validating a multidimensional treatment decision score predicting the 24-month outcome in untreated patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis, the ProVal-MS study. Neurological research and practice, 6(1), 15. https:\/\/doi.org\/10.1186\/s42466-024-00310-x.","DOI":"10.1186\/s42466-024-00310-x."},{"issue":"11","key":"419_CR26","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/wnl.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke, J. F. (1983). Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology, 33(11), 1444\u20131452. https:\/\/doi.org\/10.1212\/wnl.33.11.1444","journal-title":"Neurology"},{"issue":"4","key":"419_CR27","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1177\/135245850000600411","volume":"6","author":"M Kaufman","year":"2000","unstructured":"Kaufman, M., Moyer, D., & Norton, J. (2000). The significant change for the timed 25-foot walk in the multiple sclerosis functional composite. Multiple Sclerosis (Houndmills Basingstoke England), 6(4), 286\u2013290. https:\/\/doi.org\/10.1177\/135245850000600411","journal-title":"Multiple Sclerosis (Houndmills Basingstoke England)"},{"issue":"9","key":"419_CR28","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","volume":"77","author":"L Kappos","year":"2020","unstructured":"Kappos, L., Wolinsky, J. S., Giovannoni, G., Arnold, D. L., Wang, Q., Bernasconi, C., Model, F., Koendgen, H., Manfrini, M., Belachew, S., & Hauser, S. L. (2020). Contribution of Relapse-Independent progression vs Relapse-Associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurology, 77(9), 1132\u20131140. https:\/\/doi.org\/10.1001\/jamaneurol.2020.1568","journal-title":"JAMA Neurology"},{"issue":"8","key":"419_CR29","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S1474-4422(21)00095-8","volume":"20","author":"MP Wattjes","year":"2021","unstructured":"Wattjes, M. P., Ciccarelli, O., Reich, D. S., Banwell, B., de Stefano, N., Enzinger, C., Fazekas, F., Filippi, M., Frederiksen, J., Gasperini, C., Hacohen, Y., Kappos, L., Li, D. K. B., Mankad, K., Montalban, X., Newsome, S. D., Oh, J., Palace, J., Rocca, M. A., Sastre-Garriga, J., & North American Imaging in Multiple Sclerosis Cooperative MRI guidelines working group. (2021). 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. The Lancet Neurology, 20(8), 653\u2013670. https:\/\/doi.org\/10.1016\/S1474-4422(21)00095-8","journal-title":"The Lancet Neurology"},{"key":"419_CR30","unstructured":"Dati, F., Schumann, G., Thomas, L., Aguzzi, F., Baudner, S., Bienvenu, J., Blaabjerg, O., Blirup-Jensen, S., Carlstr\u00f6m, A., Petersen, P. H., Johnson, A. M., Milford-Ward, A., Ritchie, R. F., Svendsen, P. J., & Whicher, J. (1996). Consensus of a group of professional societies and diagnostic companies on guidelines for interim reference ranges for 14 proteins in serum based on the standardization against the IFCC\/BCR\/CAP Reference Material (CRM 470). International Federation of Clinical Chemistry. Community Bureau of Reference of the Commission of the European Communities. College of American Pathologists. European journal of clinical chemistry and clinical biochemistry: journal of the Forum of European Clinical Chemistry Societies, 34(6), 517\u2013520."},{"issue":"9","key":"419_CR31","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/clinchem\/48.9.1437","volume":"48","author":"JA Katzmann","year":"2002","unstructured":"Katzmann, J. A., Clark, R. J., Abraham, R. S., Bryant, S., Lymp, J. F., Bradwell, A. R., & Kyle, R. A. (2002). Serum reference intervals and diagnostic ranges for free kappa and free lambda Immunoglobulin light chains: Relative sensitivity for detection of monoclonal light chains. Clinical Chemistry, 48(9), 1437\u20131444.","journal-title":"Clinical Chemistry"},{"key":"419_CR32","doi-asserted-by":"publisher","unstructured":"Cossarizza, A., Chang, H. D., Radbruch, A., Abrignani, S., Addo, R., Akdis, M., Andr\u00e4,I., Andreata, F., Annunziato, F., Arranz, E., Bacher, P., Bari, S., Barnaba, V., Barros-Martins,J., Baumjohann, D., Beccaria, C. G., Bernardo, D., Boardman, D. A., Borger, J., B\u00f6ttcher,C., \u2026 Yang, J. (2021). Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition). European journal of immunology, 51(12), 2708\u20133145. https:\/\/doi.org\/10.1002\/eji.202170126.","DOI":"10.1002\/eji.202170126."},{"issue":"11","key":"419_CR33","doi-asserted-by":"publisher","first-page":"5094","DOI":"10.1182\/blood.V106.11.5094.5094","volume":"106","author":"M Das","year":"2005","unstructured":"Das, M., Mead, G. P., Sreekanth, V., Anderson, J., Blair, S., Howe, T., Cavet, J., & Liakopoulou, E. (2005). Serum free light chain (SFLC) concentration kinetics in patients receiving bortezomib: Temporary Inhibition of protein synthesis and early biomarker for disease response. Blood, 106(11), 5094. https:\/\/doi.org\/10.1182\/blood.V106.11.5094.5094","journal-title":"Blood"},{"issue":"11","key":"419_CR34","doi-asserted-by":"publisher","first-page":"4865","DOI":"10.1182\/blood.V104.11.4865.4865","volume":"104","author":"GP Mead","year":"2004","unstructured":"Mead, G. P., Reid, S. D., Augustson, B. M., Drayson, M. T., Bradwell, A. R., & Child, J. A. (2004). Correlation of serum free light chains and bone marrow plasma cell infiltration in multiple myeloma. Blood, 104(11), 4865. https:\/\/doi.org\/10.1182\/blood.V104.11.4865.4865","journal-title":"Blood"},{"key":"419_CR35","doi-asserted-by":"publisher","first-page":"1454747","DOI":"10.3389\/fimmu.2024.1454747","volume":"15","author":"WH Robinson","year":"2024","unstructured":"Robinson, W. H., Fiorentino, D., Chung, L., Moreland, L. W., Deodhar, M., Harler, M. B., Saulsbery, C., & Kunder, R. (2024). Cutting-edge approaches to B-cell depletion in autoimmune diseases. Frontiers in Immunology, 15, 1454747. https:\/\/doi.org\/10.3389\/fimmu.2024.1454747","journal-title":"Frontiers in Immunology"},{"key":"419_CR36","doi-asserted-by":"publisher","unstructured":"Willison, A. G., Hagler, R., Weise, M., Elben, S., Huntemann, N., Masanneck, L.,Pfeuffer, S., Lichtenberg, S., Golombeck, K. S., Preuth, L. M., Rolfes, L., \u00d6zt\u00fcrk,M., Ruck, T., Melzer, N., Korsen, M., Hauser, S. L., Hartung, H. P., Lang, P. A.,Pawlitzki, M., R\u00e4uber, S., \u2026 Meuth, S. G. (2025). Effects of Anti-CD20 Antibody Therapy on Immune Cell Dynamics in Relapsing-Remitting Multiple Sclerosis. Cells, 14(7), 552. https:\/\/doi.org\/10.3390\/cells14070552.","DOI":"10.3390\/cells14070552."},{"key":"419_CR37","doi-asserted-by":"publisher","first-page":"117957352110421","DOI":"10.1177\/11795735211042166","volume":"13","author":"FF Konen","year":"2021","unstructured":"Konen, F. F., Schwenkenbecher, P., Wurster, U., Jendretzky, K. F., M\u00f6hn, N., Gingele, S., S\u00fchs, K. W., Hannich, M. J., Grothe, M., Witte, T., Stangel, M., S\u00fc\u00dfe, M., & Skripuletz, T. (2021). The influence of renal function impairment on kappa free light chains in cerebrospinal fluid. Journal of Central Nervous System Disease, 13, 11795735211042166. https:\/\/doi.org\/10.1177\/11795735211042166","journal-title":"Journal of Central Nervous System Disease"},{"issue":"1","key":"419_CR38","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1515\/cclm-2023-1468","volume":"63","author":"MJ Hannich","year":"2024","unstructured":"Hannich, M. J., Konen, F. F., Gag, K., Alkhayer, A., T\u00fcrker, S. N., Budde, K., Nauck, M., Wurster, U., Dressel, A., Skripuletz, T., & S\u00fc\u00dfe, M. (2024). Implications of monoclonal gammopathy and isoelectric focusing pattern 5 on the free light chain kappa diagnostics in cerebrospinal fluid. Clinical Chemistry and Laboratory Medicine, 63(1), 147\u2013153. https:\/\/doi.org\/10.1515\/cclm-2023-1468","journal-title":"Clinical Chemistry and Laboratory Medicine"},{"issue":"1","key":"419_CR39","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/s0022-510x(97)00272-4","volume":"155","author":"H Tumani","year":"1998","unstructured":"Tumani, H., Tourtellotte, W. W., Peter, J. B., & Felgenhauer, K. (1998). Acute optic neuritis: Combined immunological markers and magnetic resonance imaging predict subsequent development of multiple sclerosis. The optic neuritis study group. Journal of the Neurological Sciences, 155(1), 44\u201349. https:\/\/doi.org\/10.1016\/s0022-510x(97)00272-4","journal-title":"Journal of the Neurological Sciences"},{"issue":"4","key":"419_CR40","doi-asserted-by":"publisher","first-page":"e573","DOI":"10.1212\/NXI.0000000000000573","volume":"6","author":"A Klein","year":"2019","unstructured":"Klein, A., Selter, R. C., Hapfelmeier, A., Berthele, A., M\u00fcller-Myhsok, B., Pongratz, V., Gasperi, C., Zimmer, C., M\u00fchlau, M., & Hemmer, B. (2019). CSF parameters associated with early MRI activity in patients with MS. Neurology(R) Neuroimmunology & Neuroinflammation, 6(4), e573. https:\/\/doi.org\/10.1212\/NXI.0000000000000573","journal-title":"Neurology(R) Neuroimmunology & Neuroinflammation"},{"issue":"11","key":"419_CR41","doi-asserted-by":"publisher","first-page":"e0143375","DOI":"10.1371\/journal.pone.0143375","volume":"10","author":"G Makshakov","year":"2015","unstructured":"Makshakov, G., Nazarov, V., Kochetova, O., Surkova, E., Lapin, S., & Evdoshenko, E. (2015). Diagnostic and prognostic value of the cerebrospinal fluid concentration of Immunoglobulin free light chains in clinically isolated syndrome with conversion to multiple sclerosis. PloS One, 10(11), e0143375. https:\/\/doi.org\/10.1371\/journal.pone.0143375","journal-title":"PloS One"},{"issue":"3","key":"419_CR42","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1177\/135245859500100303","volume":"1","author":"RA Rudick","year":"1995","unstructured":"Rudick, R. A., Medendorp, S. V., Namey, M., Boyle, S., & Fischer, J. (1995). Multiple sclerosis progression in a natural history study: Predictive value of cerebrospinal fluid free kappa light chains. Multiple Sclerosis (Houndmills Basingstoke England), 1(3), 150\u2013155. https:\/\/doi.org\/10.1177\/135245859500100303","journal-title":"Multiple Sclerosis (Houndmills Basingstoke England)"},{"key":"419_CR43","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.msard.2019.02.001","volume":"30","author":"D Vecchio","year":"2019","unstructured":"Vecchio, D., Crespi, I., Virgilio, E., Naldi, P., Campisi, M. P., Serino, R., Dianzani, U., Bellomo, G., Cantello, R., & Comi, C. (2019). Kappa free light chains could predict early disease course in multiple sclerosis. Multiple Sclerosis and Related Disorders, 30, 81\u201384. https:\/\/doi.org\/10.1016\/j.msard.2019.02.001","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"419_CR44","doi-asserted-by":"publisher","first-page":"577355","DOI":"10.1016\/j.jneuroim.2020.577355","volume":"347","author":"M Salavisa","year":"2020","unstructured":"Salavisa, M., Paix\u00e3o, P., Ladeira, A. F., Mendes, A., Correia, A. S., Viana, J. F., & Viana-Baptista, M. (2020). Prognostic value of kappa free light chains determination in first-ever multiple sclerosis relapse. Journal of Neuroimmunology, 347, 577355. https:\/\/doi.org\/10.1016\/j.jneuroim.2020.577355","journal-title":"Journal of Neuroimmunology"},{"issue":"4","key":"419_CR45","doi-asserted-by":"publisher","first-page":"e1005","DOI":"10.1212\/NXI.0000000000001005","volume":"8","author":"K Berek","year":"2021","unstructured":"Berek, K., Bsteh, G., Auer, M., Di Pauli, F., Grams, A., Milosavljevic, D., Poskaite, P., Schnabl, C., Wurth, S., Zinganell, A., Berger, T., Walde, J., Deisenhammer, F., & Hegen, H. (2021). Kappa-Free light chains in CSF predict early multiple sclerosis disease activity. Neurology(R) Neuroimmunology & Neuroinflammation, 8(4), e1005. https:\/\/doi.org\/10.1212\/NXI.0000000000001005","journal-title":"Neurology(R) Neuroimmunology & Neuroinflammation"},{"issue":"10","key":"419_CR46","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1007\/s00415-008-0954-z","volume":"255","author":"S Presslauer","year":"2008","unstructured":"Presslauer, S., Milosavljevic, D., Br\u00fccke, T., Bayer, P., & H\u00fcbl, W. (2008). Elevated levels of kappa free light chains in CSF support the diagnosis of multiple sclerosis. Journal of Neurology, 255(10), 1508\u20131514. https:\/\/doi.org\/10.1007\/s00415-008-0954-z","journal-title":"Journal of Neurology"},{"issue":"1\u20132","key":"419_CR47","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jneuroim.2013.07.006","volume":"263","author":"F Duranti","year":"2013","unstructured":"Duranti, F., Pieri, M., Centonze, D., Buttari, F., Bernardini, S., & Dessi, M. (2013). Determination of \u03baFLC and \u03ba index in cerebrospinal fluid: A valid alternative to assess intrathecal Immunoglobulin synthesis. Journal of Neuroimmunology, 263(1\u20132), 116\u2013120. https:\/\/doi.org\/10.1016\/j.jneuroim.2013.07.006","journal-title":"Journal of Neuroimmunology"},{"issue":"4","key":"419_CR48","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1007\/s10875-005-5371-9","volume":"25","author":"S Desplat-J\u00e9go","year":"2005","unstructured":"Desplat-J\u00e9go, S., Feuillet, L., Pelletier, J., Bernard, D., Ch\u00e9rif, A. A., & Boucraut, J. (2005). Quantification of Immunoglobulin free light chains in cerebrospinal fluid by nephelometry. Journal of Clinical Immunology, 25(4), 338\u2013345. https:\/\/doi.org\/10.1007\/s10875-005-5371-9","journal-title":"Journal of Clinical Immunology"},{"key":"419_CR49","doi-asserted-by":"publisher","first-page":"577108","DOI":"10.1016\/j.jneuroim.2019.577108","volume":"339","author":"L Gaetani","year":"2020","unstructured":"Gaetani, L., Di Carlo, M., Brachelente, G., Valletta, F., Eusebi, P., Mancini, A., Gentili, L., Borrelli, A., Calabresi, P., Sarchielli, P., Ferri, C., Villa, A., & Di Filippo, M. (2020). Cerebrospinal fluid free light chains compared to oligoclonal bands as biomarkers in multiple sclerosis. Journal of Neuroimmunology, 339, 577108. https:\/\/doi.org\/10.1016\/j.jneuroim.2019.577108","journal-title":"Journal of Neuroimmunology"},{"issue":"6","key":"419_CR50","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s12026-018-9058-8","volume":"66","author":"V Nazarov","year":"2018","unstructured":"Nazarov, V., Makshakov, G., Kalinin, I., Lapin, S., Surkova, E., Mikhailova, L., Gilburd, B., Skoromets, A., & Evdoshenko, E. (2018). Concentrations of Immunoglobulin free light chains in cerebrospinal fluid predict increased level of brain atrophy in multiple sclerosis. Immunologic Research, 66(6), 761\u2013767. https:\/\/doi.org\/10.1007\/s12026-018-9058-8","journal-title":"Immunologic Research"},{"key":"419_CR51","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.msard.2018.08.002","volume":"25","author":"M Puthenparampil","year":"2018","unstructured":"Puthenparampil, M., Altinier, S., Stropparo, E., Zywicki, S., Poggiali, D., Cazzola, C., Toffanin, E., Ruggero, S., Grassivaro, F., Zaninotto, M., Plebani, M., & Gallo, P. (2018). Intrathecal K free light chain synthesis in multiple sclerosis at clinical onset associates with local IgG production and improves the diagnostic value of cerebrospinal fluid examination. Multiple Sclerosis and Related Disorders, 25, 241\u2013245. https:\/\/doi.org\/10.1016\/j.msard.2018.08.002","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"1\u20132","key":"419_CR52","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jneuroim.2014.08.003","volume":"276","author":"G Hassan-Smith","year":"2014","unstructured":"Hassan-Smith, G., Durant, L., Tsentemeidou, A., Assi, L. K., Faint, J. M., Kalra, S., Douglas, M. R., & Curnow, S. J. (2014). High sensitivity and specificity of elevated cerebrospinal fluid kappa free light chains in suspected multiple sclerosis. Journal of Neuroimmunology, 276(1\u20132), 175\u2013179. https:\/\/doi.org\/10.1016\/j.jneuroim.2014.08.003","journal-title":"Journal of Neuroimmunology"}],"container-title":["Neurological Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-025-00419-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42466-025-00419-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-025-00419-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T15:34:13Z","timestamp":1757604853000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurolrespract.biomedcentral.com\/articles\/10.1186\/s42466-025-00419-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["419"],"URL":"https:\/\/doi.org\/10.1186\/s42466-025-00419-7","relation":{},"ISSN":["2524-3489"],"issn-type":[{"value":"2524-3489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,22]]},"assertion":[{"value":"20 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The investigation was approved by the Ethics Committee of MHH (8787_BO_K_2019) and followed the rules of the Declaration of Helsinki of 1964 and its later amendments. Informed consent for participation was obtained from all subjects involved in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent for publication was obtained from all subjects involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest. Outside the submitted work, some authors received honoraria for lectures, travel grants, or research grants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"58"}}